Diagnostic Value of Circulating Progranulin and Its Receptor EphA2 in Predicting the Atheroma Burden in Patients with Coronary Artery Disease

Table 2

Spearman’s correlation of serum PGRN and EphA2 levels with risk factors and the Gensini score.

Variable	PGRN (ng/mL)		EphA2 (pg/mL)
		value		value
Males, (%)	-0.003	0.964	0.103	0.148
Age (y) ()	-0.018	0.800	0.221	0.002
BMI (kg/m^2)	0.013	0.864	-0.147	0.054
Hypertension, (%)	0.016	0.818	-0.021	0.772
Diabetes mellitus, (%)	0.024	0.737	0.064	0.368
Smoking, (%)	-0.051	0.474	-0.024	0.740
eGFR (mL/min/1.73 m^2)	-0.075	0.303	-0.161	0.027
Total cholesterol (mg/dL)	0.078	0.278	0.186	0.008
LDL (mg/dL)	0.041	0.563	0.231	0.001
Hemoglobin A1c (%)	0.120	0.120	0.035	0.647
NT-proBNP (pg/mL)	0.185	0.009	0.389	<0.001
cTnT (ng/mL)	0.199	0.005	0.451	<0.001
CK-MB (U/L)	0.111	0.123	0.225	0.001
hs-CRP (mg/L)	0.182	0.010	0.278	<0.001
PGRN (ng/mL)	/	/	0.407	<0.001
EphA2 (pg/mL)	0.407	<0.001	/	/
Gensini score	0.099	0.170	0.306	<0.001
LVEF (%)	-0.215	0.003	-0.405	<0.001
CTO	0.147	0.041	0.330	<0.001

BMI: body mass index; eGFR: estimated glomerular filtration rate; LDL: low-density lipoprotein; NT-proBNP: N-terminal pro B-type natriuretic peptide; cTnT: cardiac troponin T; CK-MB: creatine kinase-MB; hs-CRP: hypersensitive C-reactive protein; PGRN: progranulin; EphA2: Eph-receptor tyrosine kinase-type A2; LVEF: left ventricular ejection fraction; CTO: chronic total occlusion.